Xie F, Zoratti M, Chan K, Husereau D, Krahn M, Levine O, Clifford T, Schunemann H, Guyatt G. Toward a centralized, systematic Approach to the identification, Appraisal, and Use of Health State Utility values for reimbursement decision making: introducing the Health Utility Book (HUB). MED DECIS Mak. 2019;39(4):371–9.

Article  Google Scholar 

Rowen D, Azzabi Zouraq I, Chevrou-Severac H, van Hout B. International Regulations and Recommendations for Utility Data for Health Technology Assessment. PharmacoEconomics. 2017;35(S1):11–9.

Article  PubMed  Google Scholar 

Ara R, Brazier J, Zouraq IA. The Use of Health State Utility values in decision models. PharmacoEconomics. 2017;35(S1):77–88.

Article  PubMed  Google Scholar 

Magliano DJ, Boyko EJDA. IDF DIABETES ATLAS. Brussels: International Diabetes Federation; 2021.

Google Scholar 

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan J, Mbanya JC, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. DIABETES RES CLIN PR. 2022;183:109–19.

Article  Google Scholar 

Papatheodorou K, Banach M, Bekiari E, Rizzo M, Edmonds M. Complications of diabetes 2017. J DIABETES RES. 2018;2018:1–4.

Article  Google Scholar 

Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes Mellitus. 2021;4(13):315–409.

Google Scholar 

Redenz G, Ibaceta MC, Aceituno D, Balmaceda C, Espinoza MA. Health State Utility values of type 2 diabetes Mellitus and related complications: a systematic review and Meta-analysis. VALUE HEALTH REG ISS. 2023;34:14–22.

Article  Google Scholar 

Mok CH, Kwok HHY, Ng CS, Leung GM, Quan J. Health State Utility values for type 2 diabetes and related complications in East and Southeast Asia: a systematic review and Meta-analysis. VALUE HEALTH. 2021;24(7):1059–67.

Article  PubMed  Google Scholar 

Jing X, Chen J, Dong Y, Han D, Zhao H, Wang X, Gao F, Li C, Cui Z, Liu Y, et al. Related factors of quality of life of type 2 diabetes patients: a systematic review and meta-analysis. Volume 16. HEALTH QUAL LIFE OUT; 2018. 1.

Google Scholar 

Wang Y, Gavan SP, Steinke D, et al. The impact of age on health utility values for older women with early-stage breast cancer: a systematic review and meta-regression. Health Qual Life Outcomes. 2022;20:169.

Article  PubMed  PubMed Central  Google Scholar 

Ara R, Brazier J, Peasgood T, Paisley S. The identification, review and synthesis of Health State Utility values from the literature. PharmacoEconomics. 2017;35(S1):43–55.

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ-BRIT MED J. 2021;372:n71.

Article  Google Scholar 

Koo TK, Li MY. A Guideline of selecting and reporting Intraclass correlation coefficients for Reliability Research. J CHIROPR MED. 2016;15(2):155–63.

Article  PubMed  PubMed Central  Google Scholar 

Portney LG. in Foundations of Clinical Research: Applications to Evidence-Based Practice. 4th ed. New York: F. A. Davis Company; 2020.

Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM, Holman RR. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS) outcomes Model (UKPDS 68). Diabetologia. 2004;47(10):1747–59.

Article  CAS  PubMed  Google Scholar 

Dadwani RS, Laiteerapong N. Economic Simulation Modeling in Type 2 Diabetes. Curr Diab Rep. 2020;20(7):24.

Article  PubMed  Google Scholar 

Yi Y, Philips Z, Bergman G, Burslem K. Economic models in type 2 diabetes. CURR MED RES OPIN. 2010;26(9):2105–18.

Article  CAS  PubMed  Google Scholar 

Muchadeyi MT, Hernandez-Villafuerte K, Schlander M. Quality appraisal for systematic literature reviews of health state utility values: a descriptive analysis. BMC MED RES METHODOL. 2022;22(1):303.

Article  PubMed  PubMed Central  Google Scholar 

Papaioannou D, Brazier J, Paisley S. Systematic Searching and Selection of Health State Utility Values from the literature. VALUE HEALTH. 2013;16(4):686–95.

Article  PubMed  Google Scholar 

Papaioannou D, Brazier J, Paisley S, NICE DSU Technical Support Document 9. The identification, review and synthesis of Health State Utility values from the literature. London: National Institute for Health and Care Excellence (NICE); 2010.

Google Scholar 

Nerich V, Saing S, Gamper E, Holzner B, Pivot X, Viney R, Kemmler G. Critical appraisal of health-state utility values used in breast cancer-related cost–utility analyses. BREAST CANCER RES TR. 2017;164(3):527–36.

Article  Google Scholar 

Zoratti MJ, Pickard AS, Stalmeier PFM, Ollendorf D, Lloyd A, Chan KKW, Husereau D, Brazier JE, Krahn M, Levine M, et al. Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. Eur J Health Econ. 2021;22(5):723–33.

Article  PubMed  Google Scholar 

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions (Version 6.4). Cochrane. 2023.

Jia W, Weng J, Zhu D, Ji L, Lu J, Zhou Z, Zou D, Guo L, Ji Q, Chen L, Chen L, Dou J, Guo X, Kuang H, Li L, Li Q, Li X, Liu J, Ran X, Shi L, Song G, Xiao X, Yang L, Zhao Z, Chinese Diabetes Society. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev. 2019;35(6):e3158.

Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88(11):1254–64.

Article  PubMed  PubMed Central  Google Scholar 

Adults Older. Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S139–47.

Google Scholar 

Abadie A, Athey S, Imbens GW, Wooldridge JM. When should you adjust standard errors for clustering? Q J Econ. 2023;138(1):1–35.

Article  Google Scholar 

Draper NR, Smith H. Applied Regression Analysis. Volume 326. Wiley; 1998.

Book  Google Scholar 

StataCorp. Stata Statistical Software: Release 18. In., College Station, TX: StataCorp LLC edn; 2023.

Google Scholar 

Adibe MO, Ukwe CV, Aguwa CN. The impact of pharmaceutical care intervention on the quality of life of Nigerian patients receiving treatment for type 2 diabetes. VALUE HEALTH REG ISS. 2013;2(2):240–7.

Article  Google Scholar 

Al-Azayzih A, Kanaan RJ, Altawalbeh SM. Assessment of Drug-related problems and Health-Related Quality of Life Domains in Elderly patients with type 2 diabetes Mellitus. THER CLIN RISK MANAG. 2023;19:913–28.

Article  PubMed  PubMed Central  Google Scholar 

Alshayban D, Joseph R. Health-related quality of life among patients with type 2 diabetes mellitus in Eastern Province, Saudi Arabia: a cross-sectional study. PLoS ONE. 2020;15(1):e227573.

Article  Google Scholar 

Ananthesh L, Cutinha RM, Sahoo SS, Dsouza JD, Shetty S, Gururaj C, Kellarai A. Effect of healthcare expenditure on the health related quality of life among diabetic patients of South India: a cross- sectional study. CLIN EPIDEMIOL GLOB; 2024. p. 25.

Google Scholar 

Anirudh M, Karthikeyan K. Pharmacoeconomic Evaluation of Antidiabetic Therapy at a Tertiary Health Care Institution. Asian J Pharm Clin Res. 2021;14(6):115–20.

CAS  Google Scholar 

Arifin B, Idrus LR, van Asselt ADI, Purba FD, Perwitasari DA, Thobari JA, Cao Q, Krabbe PFM, Postma MJ. Health-related quality of life in Indonesian type 2 diabetes mellitus outpatients measured with the Bahasa version of EQ-5D. Qual Life Res. 2019;28(5):1179–90.

Article  PubMed  PubMed Central  Google Scholar 

Boye KS, Yurgin N, Dilla T, Cordero LA, Badia X, Suriñach NL, Pérez P. Health-related quality of life of patients with type 2 diabetes mellitus in primary care in Spain: self-reported and proxy assessment using the EQ-5D. J MED ECON. 2007;10(1):41–58.

Article  Google Scholar 

Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. EUR J HEALTH ECON. 2011;12(3):219–30.

Article  PubMed  Google Scholar 

Boye KS, Sapin H, García-Pérez LE, Rosilio M, Orsini Federici M, Heitmann E, Jung H, Aigner U, Guerci B, Giorgino F, et al. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in type 2 diabetes patients (TROPHIES): baseline patient-reported outcomes. DIABETES THER. 2020;11(10):2383–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boye KS, Thieu VT, Sapin H, Lee CJ, Landó LF, Brown K, Bray R, Wiese RJ, Patel H, Rodríguez Á, et al. Patient-reported outcomes in people with type 2 diabetes receiving Tirzepatide in the SURPASS Clinical Trial Programme. DIABETES THER; 2023.

Book  Google Scholar 

Briggs AH, Bhatt DL, Scirica BM, Raz I, Johnston KM, Szabo SM, Bergenheim K, Mukherjee J, Hirshberg B, Mosenzon O. Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: a subanalysis from the Saxagliptin Assessment of Vascular outcomes recorded in patients with diabetes Mellitus (SAVOR)-TIMI 53 trial. DIABETES RES CLIN PR. 2017;130:24–33.

Article  CAS